CARMIEL, Israel--(BUSINESS WIRE)--Protalix BioTherapeutics, Inc. (Amex: PLX), today announced that it intends to initiate a double-blind, follow-on extension study as part of the Company’s on-going phase III clinical trial of its lead product candidate, prGCD, a proprietary plant cell expressed recombinant form of human Glucocerebrosidase (GCD) for the treatment of Gaucher disease, a lysosomal storage disorder in humans.
